$MRK Company News Merck, J.P. Morgan lead Dow decliners

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$MRK Company News

Merck, J.P. Morgan lead Dow decliners 9:35 a.m. Nov. 13, 2013 - Laura Mandaro
Merck, Cisco lead gainers in Dow industrials 4:03 p.m. Nov. 12, 2013 - Polya Lesova
Everything you need to know about buying Bitcoins 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Planned layoffs up 13.5% in October: Challenger 7:30 a.m. Nov. 6, 2013 - Steve Goldstein
Newscast: S&P 500 notches year's 32nd record high 8:08 p.m. Oct. 28, 2013 - MarketWatch
J.C. Penney, Bristol-Myers top S&P 500 7:08 p.m. Oct. 28, 2013 - Saumya Vaishampayan
S&P up for 8th day in 9; Dow, Nasdaq flat 4:57 p.m. Oct. 28, 2013 - Victor Reklaitis
Newscast: Stocks mixed after lackluster day 4:26 p.m. Oct. 28, 2013 - MarketWatch
Newscast: Car reliability ranks get new members 2:28 p.m. Oct. 28, 2013 - MarketWatch
Merck shares stumble on earnings weakness, talk of divesting assets 10:58 a.m. Oct. 28, 2013 - blogs.marketwatch.com
Merck, down 2.2%, leads Dow average lower 9:34 a.m. Oct. 28, 2013 - Laura Mandaro
Stock futures continue to waver after data 9:30 a.m. Oct. 28, 2013 - Sara Sjolin
Apple is Monday’s stock to watch as results loom 8:21 a.m. Oct. 28, 2013 - Sue Chang
Merck profit down 35% as Singulair sales fall 7:25 a.m. Oct. 28, 2013 - MarketWatch.com
Merck third-quarter profit, revenue fall 7:17 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck narrows 2013 EPS guidance; holds sales view 7:10 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 adj. EPS edges down to $0.92 vs. $0.95 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 sales down to $11.03 bln vs. $11.49 bln 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 profit falls to $1.12 bln vs. $1.73 bln 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan
Merck Q3 EPS falls to $0.38 from $0.56 year ago 7:03 a.m. Oct. 28, 2013 - Saumya Vaishampayan


Losing Some Sparkle to Buybacks 3:10 a.m. Nov. 30, 2013 - Barrons.com
Merck's Noxafil Tablets Approved by the FDA - Analyst Blog 11:30 a.m. Nov. 29, 2013 - Zacks.com
Buy Today: Merck & Co Inc's Buy Recommendation Reiterated 9:00 a.m. Nov. 29, 2013 - TheStreet.com
Drug Stocks: Winners, Losers, in Statin Shift 10:41 p.m. Nov. 27, 2013 - Barrons.com
Updated statin guidelines give AstraZeneca the upper hand: Barron's 10:54 a.m. Nov. 27, 2013 - Seeking Alpha
GlaxoSmithKline: What's The Next Growth Driver? 2:38 p.m. Nov. 26, 2013 - Seeking Alpha
Dow Today: Merck (MRK) Lower 12:16 p.m. Nov. 26, 2013 - TheStreet.com
Cramer's Mad Money - First Solar's Day In The Sun (11/25/13) 5:54 a.m. Nov. 26, 2013 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: A Glass-Half-Full Market 8:25 p.m. Nov. 25, 2013 - TheStreet.com
Can Pfizer Continue to Outperform? 5:29 p.m. Nov. 25, 2013 - Wall St. Cheat Sheet
Disney’s Pixar Studios Lays Off Workers Following ‘The Good Dinosaur’ Delay 1:17 p.m. Nov. 25, 2013 - Wall St. Cheat Sheet
$112 Billion Fund Down On Stocks: Except These 12:05 p.m. Nov. 25, 2013 - Seeking Alpha
5 Drugs Stocks Moving The Industry Upward 12:03 p.m. Nov. 25, 2013 - TheStreet.com
Stock Market News for November 25, 2013 - Market News 10:06 a.m. Nov. 25, 2013 - Zacks.com
Achillion Pharmaceuticals: 3 Different Insiders Have Purchased Shares This Month 8:59 a.m. Nov. 25, 2013 - Seeking Alpha
Recent Cloud IPO Veeva Systems Scores In Health Biz 3:31 p.m. Nov. 22, 2013 - Investors Business Daily
Watch For Today's Momo Momentum Stock: Merck (MRK) 12:05 p.m. Nov. 22, 2013 - TheStreet.com
Dow Today: Merck (MRK) Higher 12:00 p.m. Nov. 22, 2013 - TheStreet.com
Gilead Hepatitis C Drug Wins EU Panel Vote Early 10:28 a.m. Nov. 22, 2013 - Investors Business Daily
Merck & Co Inc (MRK): Today's Featured Drugs Winner 5:00 p.m. Nov. 21, 2013 - TheStreet.com


FDA Approvals, Stock Price Updates, New Study Results, Conference Schedules and Partnerships - Research Report on Merck, Pharmacyclics, UnitedHealth Group, Medtronic, and AstraZeneca 8:00 a.m. Nov. 29, 2013 - PR Newswire
Merck Announces Increased Quarterly Dividend 2:18 p.m. Nov. 26, 2013 - BusinessWire
FDA Approves Merck's NOXAFIL(R) (posaconazole) Delayed-Release Tablets 9:00 a.m. Nov. 26, 2013 - BusinessWire
Stock Price Movements and Program Launches Reported by Healthcare Companies - Research Report on Merck, Abiomed, Alere, Raptor Pharmaceuticals and West Pharmaceutical Services 8:00 a.m. Nov. 26, 2013 - PR Newswire
SiSense Wins Quarter Million Dollar Prize, Takes Top Honor in "Take the H.E.L.M." Competition 11:30 a.m. Nov. 25, 2013 - PR Newswire
Mondo Guerra and the Merck HIV Educational Campaign I Design Invite the Community to Pledge Action in Honor of World AIDS Day 8:01 a.m. Nov. 25, 2013 - PR Newswire
ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy 8:00 a.m. Nov. 25, 2013 - PR Newswire
European Patent Office Issues Decision Regarding Universal Display's Organometallic Iridium Patent 9:01 a.m. Nov. 22, 2013 - BusinessWire
Sixth Annual Biotech Showcase(TM) Returns to San Francisco January 13-15 6:51 p.m. Nov. 21, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
Merck Consumer Health Turnaround on Track 4:00 a.m. Nov. 21, 2013 - BusinessWire
Critical Alerts For Netflix, Salesforce.com, Goldman Sachs, Merck, and Valero Energy Released By InvestorsObserver 9:31 a.m. Nov. 19, 2013 - PR Newswire
Merck for Mothers Working to End the Tragedy of Women in America Dying in Childbirth and Pregnancy 8:30 a.m. Nov. 19, 2013 - PR Newswire
Additional Interim Data for Merck's Investigational Anti-PD-1 Immunotherapy, MK-3475, Shows Estimated Overall Survival Rate of 81 Percent at One Year in Patients with Advanced Melanoma 12:00 p.m. Nov. 18, 2013 - BusinessWire
Merck Partners With TRUSTe to Become Certified Under APEC Cross Border Privacy Rules 9:00 a.m. Nov. 18, 2013 - Marketwire
Merck's New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review 8:30 a.m. Nov. 18, 2013 - BusinessWire
RedHill Biopharma Announces Positive Scientific Advice Meeting and European Marketing Application Strategy for RHB-103 (Migraine) 8:00 a.m. Nov. 18, 2013 - GlobeNewswire
Interim Data to Be Presented for MK-3475, Merck's Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma 5:00 p.m. Nov. 15, 2013 - BusinessWire
Akorn Acquires Three Branded Ophthalmic Products from Merck 9:00 a.m. Nov. 15, 2013 - BusinessWire
Merck Strengthens its Presence in China with New Pharmaceutical Manufacturing Facility 2:00 a.m. Nov. 15, 2013 - PR Newswire

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Class Action Over Tumultuous Trial Results

Updated Category News Views 3

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Continue Reading
Big Wins at Americas Cardroom's $15M Venom Series

Updated Category News Views 0

High Stakes and Huge Paydays: The Venom Breakdown Alright, folks, here's a tale of how the cards fell in one of the most electrifying poker standoffs at Americas Cardroom. With prize pools clocking in at a staggering $15.095 million, the Dual Mystery Bounty Venoms really stacked the chips high. From the gritty, bustling halls of the internet to the proverbial green-felt...

Continue Reading
Drunk Angel Celebrates First Year in Crystal Jewelry

Updated Category News Views 2

One Year Down, A Unique Path Forward It's been a year since Drunk Angel jumped into the online jewelry scene, and they're setting themselves apart in their own glittery lane. Imagine starting a brand that's not just about pretty trinkets, but about linking those tiny treasures to timeless traditions. They've got their sights set on blending the deep tales of gemstones...

Continue Reading
Celebree Elevates Early Ed with New Certification Push

Updated Category News Views 0

A New Standard in Early Childhood Education In the cutthroat world of childcare and early education, just meeting the state standards ain't cutting it anymore. Celebree School, known for its infant, toddler, and preschool programs, is shaking things up with its 'Celebree Certified' initiative, setting a brand-new benchmark for teacher readiness that's far beyond the usual...

Continue Reading
Lida Group Expands Global Modular Construction Services

Updated Category News Views 5

Modular Construction's Expanding Footprint Behold Lida Group—a titan in the world of modular construction—taking ambitious strides into the global arena, reaching from the sand dunes of Saudi Arabia to the bustling corridors of the United Nations. If you haven't been paying attention, now's the time to get your head in the game. Their expansion isn't just about...

Continue Reading
Jollibee and DreamWorks Unite for Cultural Celebration

Updated Category News Views 1

Jollibee Partners with DreamWorks Animation Never thought I’d see the day: Jollibee, that familiar face of fast food, teaming up with the creative juggernaut DreamWorks Animation. They’re calling it a celebration of friendship and Filipino culture, wrapped up neatly in the context of a flick called Forgotten Island. Set to sizzle in theaters on September 25, 2026,...

Continue Reading
Dentsply Sirona Faces Insider Troubles: An Investor Call

Updated Category News Views 3

Are Dentsply Sirona Insiders on Thin Ice? The stock market's a tumultuous sea, and right now, it seems like some of those at the helm of Dentsply Sirona Inc. might be rocking the boat a bit too much. Let me tell you, navigating these corporate storms isn't for the faint-hearted. The latest noise coming from Halper Sadeh LLC suggests that some directors and officers over...

Continue Reading
DoorDash Speeds Up Gifting: Same-Day Delivery Wins

Updated Category News Views 3

Transforming Urgent Gift-Giving with Local Delivery Ever found yourself scrambling for a last-minute gift when time seems to be slipping away? That's where DoorDash steps up, changing the game with their same-day delivery options. In the fast-paced world we're living in, folks aren't just leaning on DoorDash for takeout anymore. They're pushing it as a lifeline for...

Continue Reading
Supernova SPAC Lawsuit: Settlement Proposed, $3M on Table

Updated Category News Views 3

Legal Clouds Over Supernova's SPAC Adventure Alright, folks, buckle up, because whenever you mix SPACs and lawsuits, you're in for a roller coaster. Supernova Partners Acquisition Company, Inc. stands right at the heart of a class action lawsuit, and it's been cooking ever since the court in Delaware gave it a nudge forward. Settlement Talk: What's on the Table? So here's...

Continue Reading
York Space Systems Faces Investor Lawsuit Over Claims

Updated Category News Views 1

Allegations Stir the Pot: York Space Systems Under Fire Now we're sailing into choppy waters with York Space Systems (YSS). There's a full-blown ruckus stirring as investors take aim at the company, thanks to a class action lawsuit alleging securities fraud. The legal beagles from Glancy Prongay Wolke & Rotter LLP are spearheading this effort, claiming that York pulled...

Continue Reading

Top 5 Most Recently Viewed Articles

Neumora Therapeutics: Upcoming Financial Results and Insights

Updated Category News Views 123

Neumora Therapeutics to Announce Financial Results Neumora Therapeutics, Inc. (Nasdaq: NMRA), a pioneering biopharmaceutical firm, is gearing up to share its financial outcomes for the second quarter of a future year. The conference call is set for 4:30 p.m. ET on a Wednesday, and this event aims to deliver important updates regarding their business and strategic...

Continue Reading
Exciting Insights into Claudin 6 Targeted Therapy for Cancer

Updated Category News Views 165

Introduction to TORL BioTherapeutics and TORL-1-23 TORL BioTherapeutics, LLC is leading the way in developing innovative cancer treatments, particularly focusing on antibody-drug conjugates that target Claudin 6. Their flagship product, TORL-1-23, has shown significant potential in recent clinical trials specifically aimed at patients with Claudin 6 positive cancers. This...

Continue Reading
Understanding Plasma Biomarkers for Liver Health in Youth

Updated Category News Views 118

Plasma Biomarkers and Liver Health in Adolescents Recent research has unveiled an exciting advancement in pediatric medicine regarding liver health in adolescents, particularly among Latino youth facing obesity. The study, conducted by the Children's Hospital Los Angeles, led by Principal Investigator Michael Goran, PhD, has explored the potential of plasma-based...

Continue Reading
Gruma's Market Control: A Look at Price Fixing in Mexico

Updated Category News Views 119

Cofece Ruling on Gruma's Price Fixing Authority In a significant decision that has set the stage for future pricing strategies, Mexico's antitrust authority, Cofece, announced that Gruma, a prominent player in the corn flour and tortilla market, has the ability to fix prices. This conclusion was reached following a comprehensive investigation, which revealed a lack of...

Continue Reading
Coloplast A/S Unveils Strong Financial Performance for 2024/25

Updated Category News Views 190

Coloplast A/S Interim Financial Highlights for 2024/25 Coloplast A/S has recently announced its interim financial results for the period from 1 October 2024 to 30 June 2025. This report unveils the company's impressive organic growth and highlights its strategies for maintaining its market position. Remarkable Growth Figures The latest results showcase an organic growth...

Continue Reading